|
gptkbp:instanceOf
|
gptkb:public_company
|
|
gptkbp:acquiredBy
|
gptkb:Allergan_plc
|
|
gptkbp:acquisitionYear
|
2020
|
|
gptkbp:assets
|
$146.5 billion (2023)
|
|
gptkbp:CEO
|
gptkb:Richard_A._Gonzalez
|
|
gptkbp:country
|
gptkb:United_States
|
|
gptkbp:division
|
aesthetics
immunology
neuroscience
oncology
women's health
gastroenterology
virology
eye care
|
|
gptkbp:focus
|
aesthetics
immunology
neuroscience
oncology
women's health
gastroenterology
virology
eye care
|
|
gptkbp:founded
|
2013
|
|
gptkbp:foundedBy
|
gptkb:Abbott_Laboratories
|
|
gptkbp:headquartersLocation
|
gptkb:North_Chicago,_Illinois,_United_States
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AbbVie Inc.
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:ISIN
|
US00287Y1091
|
|
gptkbp:keyPerson
|
gptkb:Azita_Saleki-Gerhardt
gptkb:Henry_O._Gosebruch
gptkb:Jeffrey_R._Stewart
gptkb:Michael_E._Severino
gptkb:Richard_A._Gonzalez
gptkb:Timothy_J._Richmond
gptkb:Laura_J._Schumacher
|
|
gptkbp:legalForm
|
gptkb:company
|
|
gptkbp:marketCap
|
over $250 billion (2024)
|
|
gptkbp:memberOf
|
gptkb:S&P_500
gptkb:S&P_100
|
|
gptkbp:netIncome
|
$4.87 billion (2023)
|
|
gptkbp:notableProduct
|
gptkb:Humira
gptkb:Imbruvica
gptkb:Rinvoq
gptkb:Skyrizi
gptkb:Venclexta
|
|
gptkbp:numberOfEmployees
|
2023
~50,000
|
|
gptkbp:operatingIncome
|
$10.2 billion (2023)
|
|
gptkbp:parentCompany
|
gptkb:Abbott_Laboratories_(spin-off_origin)
|
|
gptkbp:revenue
|
$58.05 billion (2023)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:SIC
|
2834
|
|
gptkbp:stockExchange
|
gptkb:NYSE
|
|
gptkbp:stockSymbol
|
gptkb:ABBV
|
|
gptkbp:totalEquity
|
$16.2 billion (2023)
|
|
gptkbp:type
|
public
|
|
gptkbp:website
|
https://www.abbvie.com/
|
|
gptkbp:bfsParent
|
gptkb:ABBV
|
|
gptkbp:bfsLayer
|
7
|